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Abstract
Background: Choosing the most effective approach for treating rectal cancer with mesorectal fascia (MRF)
involvement or closeness and synchronous distant metastases is a current clinical challenge. The aim of this
retrospective study was to determine if upfront systemic chemotherapy and short-course radiotherapy (RT) with
delayed surgery enables R0 resection.
Methods: Between March 2009 and October 2009, six patients were selected for upfront chemotherapy and short-
course RT (5 × 5 Gy) with delayed surgery. The patients had locally advanced primary tumors with MRF involvement
or closeness, as well as synchronous and potentially resectable distant metastases. Chemotherapy was administered
to five patients between the end of the RT and surgery. All patients underwent total mesorectal excision (TME).
Results: The median patient age was 54 years (range 39-63). All primary and metastatic lesions were resected
simultaneously. The median duration between short-course RT and surgery was 13 weeks (range, 7-18). R0
resection of rectal lesions was achieved in 5 patients. One patient, who had a very low-lying tumor, had an R1
resection. The median follow-up duration for all patients was 16.7 months (range, 15.5-23.5). One patient
developed liver metastasis at 15.7 months. There have been no local recurrences or deaths.
Conclusions: Upfront chemotherapy and short course RT with delayed surgery is a valuable alternative treatment
approach for patients with MRF involvement or closeness of rectal cancer with distant metastases.
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Background
Preoperative short-course radiotherapy (RT) or chemora-
diotherapy followed by total mesorectal excision (TME)
is an established treatment regimen for stage II and III
rectal cancer [1-4]. In addition, the mesorectal fascia
(MRF) involvement is known to predict the probability
for local tumor recurrence and patient survival [5-7].
High resolution magnetic resonance imaging (MRI) can
reliably and accurately assess the MRF involvement of
rectal masses [8-10]. A Dutch TME trial showed that
preoperative short-course RT does not compensate for
positive circumferential resection margins (CRM) [11,12].
Therefore, when either MRF involvement or closeness is
identified by MRI, patients require a treatment strategy
that induces tumor regression and thereby enables an
uninvolved MRF after TME. Conventional long-course
RT with chemotherapy followed by delayed surgery is
widely accepted as the standard approach for this patient
group [13].
It is a current and critical challenge to determine the
most effective treatment regimen for patients with MRF
involvement and potentially resectable synchronous dis-
tant metastases, which differ from widely-spread systemic
disease. In this patient group, there is a risk of distant
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metastases arising during conventional long-course che-
moradiotherapy, but also a risk of local progression in
preoperative combination chemotherapy (with or without
an antibody) regimen to target metastatic disease without
pelvic RT. Radu et al. suggested that upfront combina-
tion chemotherapy and short-course RT followed by
delayed surgery might be a useful alternative treatment
option for patients with locally advanced, non-resectable
(T4) rectal cancer and synchronous distant metastases
[14]. However, clinical evidence to support this theory is
lacking.
The aim of this retrospective study was to determine
if upfront systemic chemotherapy and short-course RT
with delayed surgery is an effective treatment regimen
for patients with MRF involvement or closeness and
synchronous distant metastases.
Methods
Patient selection
Between March 2009 and October 2009, six patients were
selected for upfront chemotherapy and short-course RT
with delayed surgery. The patients had locally advanced
primary tumors with MRF involvement or closeness, as
well as synchronous and potentially resectable distant
metastases. All patients had biopsy-confirmed adenocar-
cinoma as the primary rectal lesion. Patients had an East-
ern Cooperative Oncology Group performance scale
grade of 0, normal pre-treatment blood counts, and renal
and liver function tests. Data were collected through ret-
rospective review of medical records.
Multidisciplinary team approach
The assessments and treatment approaches were deter-
mined at a multidisciplinary team conference in the Yon-
sei Colorectal Cancer Clinic. The patients were identified
as candidates for the upfront systemic chemotherapy and
short-course RT with delayed surgery, with the intention
to perform the R0 resection for TME after tumor regres-
sion and simultaneous complete resection of metastatic
lesions. This conception was proposed by Kim NK. The
resectability of rectal and metastatic lesions was deter-
mined by the surgeon and radiologist based on imaging
studies. All patients received 4 to 9 cycles of the upfront
systemic chemotherapy with a FOLFOX based regimen
(5-FU/leucovorin/oxaliplatin combination) with or with-
out Bevacizumab (Avastin) or Cetuximab (Erbitux).
These patients received RT of 25 Gy in five fractions dur-
ing 5 consecutive work days after upfront chemotherapy.
The same chemotherapy regimen was maintained
between the end of the RT and the surgery with the
intention of allowing time for tumor regression. Che-
motherapy administered in one week after RT. One
patient did not receive chemotherapy during the regres-
sion period. The resection of the primary and metastatic
lesions was performed after re-evaluation of tumor stage
and resectability at least 6 weeks after RT.
Radiotherapy
All patients underwent planning computed tomography
(CT) in the treatment position (prone with a full bladder)
on the belly board. The gross tumor volume (GTV) was
defined as the primary tumor and any significant sur-
rounding lymphadenopathy, including lateral lymph
nodes. The clinical target volume (CTV) was defined as
follows; (1) a margin of at least 2 cm in the superior and
inferior directions was added to the GTV; (2) the lateral
margin encompassed the entire mesorectum at the level of
the GTV; (3) When there was significant lateral lymph
node involvement, a 1 cm margin was added to the GTV
in all directions. Elective nodal irradiation was not per-
formed to minimize small bowel irradiation. RT planning
was accomplished using a 5-field technique (anterior-
posterior beam, right-lateral beam, right-posterior-oblique
beam, left-posterior-oblique beam, left-lateral beam) to
cover the CTV plus 1 cm margin. The CTV was covered
within the 95% isodose line.
Tumor assessment, follow up, and statistics
Pretreatment staging work up included digital rectal exam-
ination, sigmoidoscopy, pelvic CT or MRI to evaluate local
tumor extent and the involvement of MRF, chest radiogra-
phy, CT scan of chest and abdomen, and positron emis-
sion tomography to diagnose the distant metastasis.
Imaging studies were repeated after completion of the
radiotherapy to evaluate the response and the resectability
of the rectal and metastatic lesions. Follow-up visits were
recommended at 1, 3, 6, and 12 months after surgery.
Follow-up imaging studies were performed at 1, 6, and 12
months after surgery, and treatment-related toxicities
were evaluated at every follow-up visit. We evaluated
acute toxicities between RT and surgery, which refer to
acute toxicities. Also, surgical complication was evaluated.
Toxicity was evaluated according to the Common Toxicity
Criteria Version 3.0 from the National Cancer Institute
(NCI-CTC v3.0). Data for six patients were analyzed using
SPSS version 18.0 software (SPSS Inc., Chicago, IL, USA)
Results
Patient characteristics and treatment
Patient characteristics at diagnosis are shown in Table 1.
The median age was 54 years (range 39-63 years). Four
patients were male and two were female. The tumor was
localized at the middle third for four patients, and the
lower third for two patients. The median distance from
the anal verge was 7 cm (range 1-8 cm). The tumor was
classified as T3 for three patients and T4 for three
patients. There was one patient with an N0 classification,
two with an N1 classification, and three with an N2
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classification. Five patients had MRF involvement, and
one patient had MRF closeness. All patients were diag-
nosed with distant metastasis. There were five patients
with liver metastasis, two with ovarian metastasis, and
one with peritoneal metastasis. Two patients had multi-
ple sites of distant metastasis (Patients 2 and 4). Systemic
chemotherapy prior to short-course RT was given to all
patients. All patients except Patient 4 were treated with
three to five cycles of additional systemic chemotherapy
during the interval between RT and surgery.
Treatment response and surgery
Most patients had a good clinical response based on ima-
ging after pre-operative treatment. For primary rectal
lesions, a low signal intensity change of the MRF involve-
ment on MRI imaging was observed for patients 1, 2, 3,
and 5. (Figure 1) Most metastatic lesions also regressed.
Only one lesion, which was an ovarian metastasis in
patient 4, progressed due to increased cystic fluid. All of
the primary and metastatic lesions were resected simulta-
neously. The median duration between short-course RT
and surgery was 13 weeks (range, 7-18 weeks). For pri-
mary rectal lesions, we performed low anterior resections
(Table 2). For liver metastases, we performed lobectomy,
wedge resection, or intraoperative radiofrequency abla-
tion. Patient 2 underwent left oophorectomy for the left
ovarian metastasis, and peritoneal washing cytology to
detect peritoneal seeding. Peritoneal seeding masses were
not observed during the operation. Bilateral salphingo-
oophorectomy of both ovarian metastases was performed
for Patient 4. Patient 6 showed pathologic complete
remission of the primary rectal lesion. Complete TME of
the primary rectal tumor was performed for all patients
(Table 3). The tumor size was smaller than the MRI-pre-
dicted tumor size at the time of diagnosis for all patients.
R0 resection was achieved in five patients (84%). Patient
5, who had a very low-lying tumor, had an R1 resection.
There were no malignant cells in the peritoneal washing
cytology and the left ovarian specimen from Patient 2.
Metastatic adenocarcinoma was detected for all other
metastatic lesions, which were completely resected.
Follow-up and toxicity
The median follow-up duration for all patients was 16.7
months (range, 15.5-23.5 months). The follow-up dura-
tion was defined as the interval between the date of
diagnosis and the last follow up. There was no locore-
gional recurrence in any of the patients, but distant
metastasis occurred in one patient. Patient 1 developed
distant metastases in the liver and received salvage che-
motherapy. Patient 1 survived with disease and all
patients survived with no evidence of disease.
There were no severe acute toxicities within 1 week
after short-course RT. During first chemotherapy after
RT, three patients had grade 3 diarrhea. Between RT and
surgery, 3 patients experienced acute grade 3 toxicities,
which were controlled by conservative therapy. There
were no other grade 3 or higher acute toxicity incidents.
Five patients experienced acute grade 1 fatigue. Four
patients experienced grade 1 anorexia. One patient
experienced grade 1 diarrhea. A perirectal abscess was
observed in Patient 1. He received abscess drainage and
IV antibiotics, which resolved the perirectal abscess. No
other surgical complications occurred during follow-up.
Discussion
Optimal treatment strategies for patients with unresect-
able rectal cancer and synchronous systemic metastases
are difficult to determine. Our retrospective study of six
cases demonstrated that preoperative short-course RT
with delayed surgery resulted in R0 resection for five
patients with MRF involvement or closeness of rectal
cancer and systemic metastases. In addition, upfront sys-
temic chemotherapy controlled systemic metastases until
metastatectomy.
In two European studies, preoperative short course RT
(5 × 5 Gy schedule) with TME consistently improved
the local control rate. A Dutch TME trial showed that
Table 1 Patient characteristics and treatments
Patient
No.
Age
(years)
Gender Pathology AV (cm) Initial
stage*
MRF involvement DM site Preoperative treatment
1 52 M Adeno MD 7.8 T4aN1M1a + Liver E-FOLFOX #9 + RT (25 Gy/5fx) + E-FOLFOX #3
2 39 F Adeno MD 7 T4aN0M1b + Peritoneum,
Lt. ovary
A-FOLFOX #7 + RT (25 Gy/5fx) + A-FOLFOX #2
3 56 M Adeno MD 4 T3N2aM1a + Liver FOLFOX #4 + RT (25 Gy/5fx) + FOLFOX #4
4 45 F Adeno WD 8 T3N2aM1a Threatened Liver,
both ovaries
FOLFOX #4 + RT (25 Gy/5fx)
5 63 M Adeno MD 1 T4N1aM1a + Liver FOLFOX #4 + RT (25 Gy/5fx) + FOLFOX #4
6 60 M Adeno MD 7 T3N2bM1a + Liver FOLFOX #4 + RT (25 Gy/5fx) + FOLFOX #5
Abbreviations: AV, anal verge; MRF, mesorectal fascia; adeno, adenocarcinoma; MD, moderately differentiated; Lt., left; FOLFOX, 5-fluorouracil/leucovorin/
oxaliplatin; E, erbitux; RT, radiation therapy; A, avastin.
*AJCC 7th edition.
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the 5-year local recurrence rate was 10.9% for patients
undergoing TME and 5.6% for patients undergoing pre-
operative RT [1,15]. In the Medical Research Council
CR07, the 3-year local recurrence rates for patients
undergoing TME or preoperative RT was 10.6% and
4.4%, respectively [2]. Currently, this short-course RT
schedule with immediate surgery is a widely accepted
standard treatment for rectal cancer. However, it is
increasingly clear that MRF status, as determined by
MRI scanning, has a substantial impact on the local
recurrence rate and patient survival [7,8,16]. In the sub-
group analysis of the Dutch trial, Marijnen et al.
reported that patients with positive CRMs had a local
recurrence rate of 17% and 30% after low anterior resec-
tion or abdominoperineal resection, respectively [11].
Unfortunately, postoperative treatment has not influ-
enced both survival and local recurrence in the patients
with CRM involvement. In the Medical Research Coun-
cil CR07 trial, patients with positive CRMs who under-
went postoperative chemoradiotherapy had a local
recurrence rate of 11%, which did not compensate for
positive CRMs like the subgroup analysis of the Dutch
trial [2]. On the other hand, preoperative MRI accu-
rately predicted MRF involvement or closeness in the
MERCURY Study Group [8]. Therefore, when we iden-
tify a patient with either MRF involvement or closeness
by preoperative MRI, we consider a treatment strategy
that will induce macroscopic tumor regression and steri-
lization of surgical margin to achieve R0 resection.
Immediate surgery following short-course RT is not
effective for tumor regression [12], whereas preoperative
long course radiotherapy with chemotherapy can result in
tumor down-staging [17]. Recently, a down-staging effect
was documented after delayed surgery after short-course
RT [14,18]. At Uppsala University, short course RT with
delayed surgery was performed for 46 patients with had
clinical non-resectable T4 disease with or without metas-
tases [14]. Thirty-seven (80%) patients underwent surgery.
R0 resection was achieved in 32 (86%) of these patients
and a pathologic complete response was observed for four
patients. Hatfield et al. treated 41 patients using short-
course RT with delayed surgery [18]. MRI was used to
determine the local tumor extent and its relationship with
the MRF. Twenty-two (51%) patients had a MRF closeness
(< 2 mm) and 20 (47%) had a MRF involvement. Of the 41
patients, 26 (63%) underwent surgical resection. Of the
patients undergoing surgical resection, 22 (85%) had R0
resections, and two had pathological complete responses.
These two retrospective studies show that short-course
RT with delayed surgery can result in substantial down-
staging for patients with either MRF involvement or close-
ness. In addition, R0 resection can be achieved for the
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Figure 1 MRI or CT at diagnosis and after upfront
chemotherapy and short-course RT for each patient. Arrow
points to the mesorectal fascia involvement or closeness. After
preoperative treatment, regression of rectal mass or lymph node
was observed.
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majority of the patients treated with this regimen. Toxicity
from short-course RT with delayed surgery was acceptable
and comparable to long course RT with delayed surgery.
Interim analysis of the Stockholm III trial demonstrated
the feasibility, patient compliance, side-effects of RT, and
early complications after surgery for different preoperative
radiotherapy regimens (5 × 5 Gy and immediate surgery
versus 5 × 5 Gy and delayed surgery versus conventional
fractionated 50 Gy and delayed surgery). For patients trea-
ted with short-course RT and delayed surgery, severe
acute toxicity was low (4.2%) and postoperative complica-
tions were not increased [19].
For metastatic disease, NCCN guidelines (v 2.2011)
recommend that Initial treatment options for patients
with stage IV disease with resectable liver or lung metas-
tases include combination chemotherapy that has targeted
agents, staged or synchronous resection of metastases, and
rectal lesion or treatment with chemoradiotherapy.
Upfront combination chemotherapy for the purpose of
early eradication of micrometastases can be followed by
staged or synchronous resection of metastases and rectal
lesion, or by chemoradiotherapy for local control of dis-
ease prior to surgery. For the three groups of patients that
received upfront chemotherapy, surgery should be delayed
for 5-10 weeks following completion of such treatment
[20]. However, the optimal sequence and timing of che-
motherapy, RT, and surgery still remains controversial.
For non-resectable primary rectal lesions with distant
metastases, pelvic RT is needed to achieve down-staging
and R0 resection, as well as local control of the rectal
lesion prior to surgery. Simultaneously, systemic che-
motherapy without dose reduction to control metastases is
warranted. Upfront chemotherapy and short-course RT
with delayed surgery is an attractive option in this clinical
situation. Radu C et al. reported the results of treatment
of 13 patients who had primary T4 tumors with synchro-
nous distant metastases [14]. These patients were treated
with systemic combination chemotherapy, integrating 5 ×
5 Gy with delayed surgery. Surgery was performed for
nine patients. R0 resection was achieved for six of the nine
patients. Subsequent metastatic surgery was possible for
two of the patients. In this study, six patients with MRF
Table 2 Surgery details and treatment outcomes after overall treatments
Patient
No.
Interval from RT to OP
(weeks)
Surgery yp Stage* Maintenance
chemotherapy
Pattern of failure Last follow
up
(months)
Survival
1 12 LAR,
Lt. lobectomy and intraop RFA
of liver
T3N1aM1a FOLFOX #4 Distant at 15.7
months
23.5 AWD
2 8 LAR,
Lt. oophorectomy
T3N0M0 A-FOLFOX #4 None 19.0 NED
3 14 LAR,
Lt. lobectomy
T3N0M1a None None 16.9 NED
4 7 LAR,
WR of Liver, BSO
T3N1aM1a FOLFOX #11 None 16.5 NED
5 14 LAR,
segmentectomy and WR of
Liver
T3N2bM1a FOLFOX #4 None 15.5 NED
6 18 LAR,
WR of liver
T0N1aM1a FOLFOX #4 None 15.8 NED
Abbreviations: RT, radiation therapy; OP, operation; LAR, low anterior resection; Lt., left; intraop, intraoperative; RFA, radiofrequency ablation; WR, wedge resection;
BSO, Bilateral salphingo-oophorectomy; FOLFOX, 5-fluorouracil/leucovorin/oxaliplatin; A, avastin; AWD, alive with disease; NED, no evidence of disease.
*AJCC 7th edition.
Table 3 Surgical pathologic reports
Patient
No.
TME Mandard
grade
Tumor
size
RM Invasion
depth
No. of LN
dissected
No. of LN
involved
LV
invasion
Metastasis pathology
1 Complete 3 4 R0 Perirectal fat tissue 9 1 - Liver; metastatic adenocarcinoma
2 Complete 2 0.7 R0 Perirectal fat tissue 18 0 - Peritoneum; negative
Lt. ovary; free from tumor
3 Complete 2 0.5 R0 Perirectal fat tissue 9 0 - Liver; metastatic adenocarcinoma
4 Complete 3 2.3 R0 Perirectal fat tissue 28 2 - Liver; metastatic adenocarcinoma
both ovaries; metastatic adenocarcinoma
5 Complete 3 2.5 R1 Perirectal fat tissue 18 8 + Liver; metastatic adenocarcinoma
6 Complete 1 0 R0 No tumor 22 1 - Liver; metastatic adenocarcinoma
Abbreviations: TME, total mesorectal excision; RM, resection margin; LN, lymph nodes; LV, lymphovascular; Lt., left.
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involvement or closeness and distant metastasis received
similar sequences of chemotherapy, short-course RT, and
delayed surgery. R0 resection of rectal lesions was possible
for five patients. Furthermore, metastatic surgery was also
successful in removing the tumor mass without evidence
of microscopic disease. We totally agree with the sugges-
tion of Radu and colleagues; Patients with MRF involve-
ment or closeness of rectal cancer and synchronous
distant metastases can be treated effectively with upfront
systemic chemotherapy, short-course RT, delayed surgery,
and systemic chemotherapy during the period of delay.
Our study has many limitations including small num-
bers, limited follow up period, heterogeneity of the com-
bination of systemic agents and duration of treatments.
Expansion to a larger study group is warranted. We are
conducting a phase II clinical trial (NCT01269229), in
which patients with MRF involvement or closeness of
rectal cancer and liver metastases are treated with
upfront systemic FOLFOX chemotherapy four cycles, 5 ×
5 Gy RT to primary rectal lesion, repeat systemic FOL-
FOX chemotherapy four cycles, and delayed surgery [21].
Conclusions
Upfront chemotherapy and short-course RT with delayed
surgery appears to be a valuable alternative treatment for
patients with MRF involvement or closeness of rectal can-
cer and distant metastases. The first advantage of this
approach is that short-course RT with delayed surgery can
result in down-staging and R0 resection for primary rectal
lesions, which prevents local recurrence. The second
advantage is that systemic chemotherapy without a dose
reduction can result in early eradication of micrometas-
tases and regression of metastatic tumor masses.
List of abbreviations
RT: radiotherapy; TME: total mesorectal excision; MRF: mesorectal fascia; CRM:
circumferential resection margin; MRI: magnetic resonance imaging; FOLFOX:
5-FU/leucovorin/oxaliplatin; CT: computed tomography; GTV: gross tumor
volume; CTV: clinical target volume.
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